ReViral begins Phase I trial of RV521 to treat respiratory syncytial virus

Anti-viral drug discovery and development company ReViral has commenced a Phase 1 clinical trial for RV521, an orally active, small-molecule inhibitor of RSV fusion.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news